Momelotinib Trial Seeks to Address Myelofibrosis Symptoms

Ruben Mesa

Mays Cancer Center

Press/Media: Press / Media

Period	Jan 6 2021

Media coverage

1

Media coverage

Title Momelotinib Trial Seeks to Address Myelofibrosis Symptoms
Media name/outlet OncLive
Country United States
Date 1/6/21
Persons Ruben Mesa

Related content

Research Output
Simplify-1: A phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor–naïve patients with myelofibrosis
Research output: Contribution to journal › Article › peer-review
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Research output: Contribution to journal › Article › peer-review